Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Enzon and Hisun Announce Strategic Alliance for PEGylation Technology in China

publication date: May 8, 2012
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Enzon and Zhejiang Hisun today announced a strategic alliance for the development of therapeutics using Enzon's Customized PEGylation Linker Technology. The agreement also included Hisun licensing China rights for Enzon’s novel anti-cancer drug, PEG-SN38. Enzon will receive an upfront fee, milestone payments and high single-digit royalties on net sales while retaining ex-China rights. Detailed financial terms of the agreement were not disclosed. More details…

Stock symbol: (NASDAQ: ENZN; SSE: 600267)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...



Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China

>>More events...
Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Partners